2180 related articles for article (PubMed ID: 33667416)
41. Alzheimer's disease.
Ballard C; Gauthier S; Corbett A; Brayne C; Aarsland D; Jones E
Lancet; 2011 Mar; 377(9770):1019-31. PubMed ID: 21371747
[TBL] [Abstract][Full Text] [Related]
42. Association between Longitudinal Cerebrospinal Fluid Alzheimer's Biomarkers and the Lifestyle for Brain Health (LIBRA) Index: Findings from the European Prevention of Alzheimer's Dementia Cohort Study (EPAD LCS).
Saunders TS; Protsiv M; Jenkins ND; Solomon A; Blennow K; Ritchie C; Muniz-Terrera G
J Prev Alzheimers Dis; 2023; 10(3):543-550. PubMed ID: 37357296
[TBL] [Abstract][Full Text] [Related]
43. Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes.
Long JM; Coble DW; Xiong C; Schindler SE; Perrin RJ; Gordon BA; Benzinger TLS; Grant E; Fagan AM; Harari O; Cruchaga C; Holtzman DM; Morris JC
Brain; 2022 Dec; 145(12):4506-4518. PubMed ID: 35867858
[TBL] [Abstract][Full Text] [Related]
44. Plasma p-tau181 as an outcome and predictor of multidomain intervention effects: a secondary analysis of a randomised, controlled, dementia prevention trial.
Coley N; Zetterberg H; Cantet C; Guyonnet S; Ashton NJ; Vellas B; Blennow K; Andrieu S;
Lancet Healthy Longev; 2024 Feb; 5(2):e120-e130. PubMed ID: 38310892
[TBL] [Abstract][Full Text] [Related]
45. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
[TBL] [Abstract][Full Text] [Related]
46. Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration.
Gonzalez-Ortiz F; Turton M; Kac PR; Smirnov D; Premi E; Ghidoni R; Benussi L; Cantoni V; Saraceno C; Rivolta J; Ashton NJ; Borroni B; Galasko D; Harrison P; Zetterberg H; Blennow K; Karikari TK
Brain; 2023 Mar; 146(3):1152-1165. PubMed ID: 36572122
[TBL] [Abstract][Full Text] [Related]
47. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
Fortea J; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L; Barroeta I; Fernández S; Altuna M; Pegueroles J; Montal V; Valldeneu S; Giménez S; González-Ortiz S; Muñoz L; Estellés T; Illán-Gala I; Belbin O; Camacho V; Wilson LR; Annus T; Osorio RS; Videla S; Lehmann S; Holland AJ; Alcolea D; Clarimón J; Zaman SH; Blesa R; Lleó A
Lancet; 2020 Jun; 395(10242):1988-1997. PubMed ID: 32593336
[TBL] [Abstract][Full Text] [Related]
48. Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials.
Siemers E; DeMattos RB; May PC; Dean RA
Biomark Med; 2010 Feb; 4(1):81-9. PubMed ID: 20387304
[TBL] [Abstract][Full Text] [Related]
49. Interactions between apolipoprotein E, sex, and amyloid-beta on cerebrospinal fluid p-tau levels in the European prevention of Alzheimer's dementia longitudinal cohort study (EPAD LCS).
Saunders TS; Jenkins N; Blennow K; Ritchie C; Muniz-Terrera G
EBioMedicine; 2022 Sep; 83():104241. PubMed ID: 36041266
[TBL] [Abstract][Full Text] [Related]
50. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
51. Are we ready to use anti-amyloid therapy in Alzheimer's disease?
Brucki SMD; César-Freitas KG; Spera RR; Borges CR; Smid J
Arq Neuropsiquiatr; 2022 May; 80(5 Suppl 1):15-23. PubMed ID: 35976307
[TBL] [Abstract][Full Text] [Related]
52. Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's disease.
Biel D; Luan Y; Brendel M; Hager P; Dewenter A; Moscoso A; Otero Svaldi D; Higgins IA; Pontecorvo M; Römer S; Steward A; Rubinski A; Zheng L; Schöll M; Shcherbinin S; Ewers M; Franzmeier N;
Alzheimers Res Ther; 2022 Nov; 14(1):166. PubMed ID: 36345046
[TBL] [Abstract][Full Text] [Related]
53. New developments in mild cognitive impairment and Alzheimer's disease.
Schott JM; Kennedy J; Fox NC
Curr Opin Neurol; 2006 Dec; 19(6):552-8. PubMed ID: 17102693
[TBL] [Abstract][Full Text] [Related]
54. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H
Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663
[TBL] [Abstract][Full Text] [Related]
55. Higher plasma β-synuclein indicates early synaptic degeneration in Alzheimer's disease.
Oeckl P; Janelidze S; Halbgebauer S; Stomrud E; Palmqvist S; Otto M; Hansson O
Alzheimers Dement; 2023 Nov; 19(11):5095-5102. PubMed ID: 37186338
[TBL] [Abstract][Full Text] [Related]
56. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification.
Barthélemy NR; Bateman RJ; Hirtz C; Marin P; Becher F; Sato C; Gabelle A; Lehmann S
Alzheimers Res Ther; 2020 Mar; 12(1):26. PubMed ID: 32183883
[TBL] [Abstract][Full Text] [Related]
57. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
58. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
[TBL] [Abstract][Full Text] [Related]
59. Associating Alzheimer's disease pathology with its cerebrospinal fluid biomarkers.
Bridel C; Somers C; Sieben A; Rozemuller A; Niemantsverdriet E; Struyfs H; Vermeiren Y; Van Broeckhoven C; De Deyn PP; Bjerke M; Nagels G; Teunissen CE; Engelborghs S
Brain; 2022 Nov; 145(11):4056-4064. PubMed ID: 35026840
[TBL] [Abstract][Full Text] [Related]
60. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.
Barthel H; Gertz HJ; Dresel S; Peters O; Bartenstein P; Buerger K; Hiemeyer F; Wittemer-Rump SM; Seibyl J; Reininger C; Sabri O;
Lancet Neurol; 2011 May; 10(5):424-35. PubMed ID: 21481640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
